Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
Constructive feedback from FDA clarifies potential Phase 3 development path forward Constructive feedback from FDA clarifies potential Phase 3 development path forward